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6-Minute walk testAnemia is common in older persons and is associatedwith substantialmorbidity andmortality. One third of ane-
mic older adults have unexplained anemia of the elderly (UAE). We carried out a randomized, wait list control
trial in outpatients with UAE and serum ferritin levels between 20 and 200 ng/mL. Intravenous iron sucrose
was given as a 200-mg weekly dose for 5 weeks either immediately after enrollment (immediate intervention
group) or following a 12-week wait list period (wait list control group). The primary outcome measure was
changed in 6-minute walk test (6MWT) distances from baseline to 12 weeks between the two groups. Hemato-
logic, physical, cognitive, and quality of life parameters were also assessed. The study was terminated early after
19 subjects enrolled. The distance walked in the 6MWT increased a mean 8.05 ± 55.48 m in the immediate in-
tervention group and decreased a mean 11.45 ± 49.46 m in the wait list control group (p= 0.443). The hemo-
globin increased a mean 0.39 ± 0.46 g/dL in the immediate intervention group and declined a mean 0.39 ±
0.85 g/dL in the wait list control group (p= 0.026). Thus, a subgroup of adults with UAE may respond to intra-
venous iron. Enrollment of subjects into this type of study remains challenging.
Published by Elsevier Inc.z@medicine.bsd.uchicago.edu
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Anemia is common in older adults, with a prevalence of approxi-
mately 10% in community-dwelling men and women aged 65 and
older, rising to 20–35% in those aged 85 and above [1,2]. Although on
an individual basis anemia in older adults is frequently overlooked or ig-
nored, studies from numerous older populations throughout the devel-
oped world have consistently demonstrated an association between
anemia, which is typically mild, and poor clinical outcomes, including
decreased physical performance and strength [3,4], decreased mobility
function [5], impairment in instrumental activities of daily living [6],
Table 1
Study entry criteria.
Inclusion criteria Exclusion criteria
1. Age ≥ 65 years old
2. Hemoglobin concentration ≥ 9.0 g/dL and b11.5 g/dL
for women and ≥9.0 to b12.7 g/dL for men
3. Unexplained anemia (see Table 2 for identiﬁable etiologies
of anemia that investigator must review)
4. Serum ferritin level ≥ 20 and ≤200 ng/mL
5. Able to walk without the use of a walker or motorized device,
or the assistance of another person
6. Able to understand and be willing to provide written informed
consent in the absence of dementia, deﬁned as a Montreal Cognitive
Assessment score ≥ 22
7. Able to understand and speak in English, or at select sites where
Spanish-speaking study staff and written informed consent in
Spanish are available and approved by the institutional review board,
Spanish-speaking subjects who do not speak English may be enrolled
1. Red blood cell transfusions in the past 3 months
2. Use of erythropoiesis stimulating agent in the past 3 months
3. Intravenous iron infusions in the past 3 months
4. Distance on baseline 6-minute walk test above age- and
sex-adjusted population median
5. History of unstable angina or myocardial infarction in
the past 3 months
6. History of stroke or transient ischemic attacks in the
past 3 months
7. Uncontrolled hypertension deﬁned as greater than the
average diastolic blood pressure N 100 mm Hg or systolic
blood pressure N 160 mm Hg on 2 separate occasions on
2 separate days during screening
8. Positive fecal occult blood test within the screening period
9. Elevated aspartate aminotransferase or alanine aminotransferase
≥ 2 × upper limit of normal
10. Documented anaphylactic reaction to iron sucrose infusion
in the past
11. Initiated on oral iron supplementation within the last 6 weeks,
or within the last 3 months and having at least a 1 g/dL improvement
in hemoglobin since starting oral iron supplementation
222 E. Price et al. / Blood Cells, Molecules and Diseases 53 (2014) 221–230increased frailty [7], impaired quality of life [8], decreased cognitive
function [9], and increased mortality [10,11].
Anemia has many causes. Data from large population-based surveys
have ascertained several broad etiologies of anemia in older adults:
iron deﬁciency that is possibly nutritional but more often secondary to
blood loss, anemia associatedwith inﬂammation, anemia due to renal in-
sufﬁciency, anemia due to nutritional deﬁciencies, and unexplained ane-
mia of the elderly (UAE). UAE, a relatively new diagnostic category, is
consistently found in approximately 30–44% of older anemic subjects
[1,2,12]. Prospective studies incorporating a thorough clinical evaluation
have demonstrated similar proportions of UAE [13,14]. Iron deﬁciency in
older adults may be difﬁcult to identify, with the diagnosis conﬁrmed
only by response to a trial of iron supplementation [13]. In addition, pa-
tientswho do not respond to oral ironmay have a rise in hemoglobin fol-
lowing the administration of intravenous iron [15]. The Partnership for
Anemia: Clinical and Translational Trials in the Elderly (PACTTE) consor-
tium was formed to investigate treatment strategies in subjects with
UAE. This study was designed as the ﬁrst PACTTE interventional study,
utilizing intravenous iron sucrose (IVIS) in a subset of subjects with UAE.
Materials and methods
Study design
The study was designed as a randomized, wait list control trial. Sub-
jects were randomized to receive IVIS either immediately after enroll-
ment (immediate intervention group) or after an initial waiting period
of 12 weeks (wait list control group). The protocol was approved by an
independent data and safety monitoring board (DSMB) as well as the in-
stitutional review board at each participating institution, and the trial was
conducted in accordance with the Declaration of Helsinki for biomedical
research involving human subjects. Written informed consent was pro-
vided by all subjects. The trial was designed, implemented, and overseen
by the PACTTE Steering Committee. An independent DSMB reviewed the
safety data and study progress on an ongoing basis.
Participants
Outpatient men and women with the following criteria were eligi-
ble to enroll: age ≥65 years with a hemoglobin concentration of
≥9 g/dL and b11.5 g/dL for women or b12.7 g/dL for men with unex-
plained anemia; serum ferritin between 20 and 200 ng/mL (inclusive);
ability to walk without the use of a walker or motorized device, or theassistance of another person; lack of signiﬁcant cognitive impairment
deﬁned by a Montreal Cognitive Assessment score of 22 or higher;
and ability to understand and speak English (Table 1). The protocol
initially included subjects with a serum ferritin between 20 and
100 ng/mL (inclusive) but was modiﬁed on March 26, 2012, due to
poor recruitment to allow serum ferritin levels between 20 and
200 ng/mL (inclusive). The protocol was additionally modiﬁed on Au-
gust 20, 2012, at sites with Spanish-speaking study staff to include sub-
jects who were able to speak and understand Spanish. Unexplained
anemia was deﬁned, similar to published criteria [13,14], as not meet-
ing criteria for any known etiology of anemia, including vitamin B12, fo-
late, or iron deﬁciency (deﬁned as serum ferritin b 20 ng/mL); renal
insufﬁciency (deﬁned as glomerular ﬁltration rate of less than 30 [16]
using the four-variable Modiﬁcation of Diet in Renal Disease equa-
tion [17]); thyroid dysfunction; myelodysplastic syndrome; anemia of
inﬂammation; plasma cell dyscrasia; thalassemia trait; alcohol overuse;
any prior history of hematologic malignancy; unexplained splenomeg-
aly or lymphadenopathy; or the presence of any condition reasonably
assumed to be causing anemia and not corrected for 3 months
(Table 2). Subjects were excluded if they had received a red blood cell
transfusion, intravenous iron, or an erythropoiesis stimulating agent
within 3 months prior to enrollment; had unstable angina, a myocardi-
al infarction, a stroke, or a transient ischemic attack within 3 months
prior to enrollment; had uncontrolled hypertension; had a positive
fecal occult blood test during the screening period; had signiﬁcant im-
pairment in liver function; had a documented history of anaphylactic
reaction to iron sucrose infusion; had recently initiated oral iron sup-
plementation; or if the distance walked on the 6-minute walk test
(6MWT) was above themedian for age and sex, to avoid a ceiling effect
(Table 1; Appendix A).
Randomization
Subjects were randomized to start IVIS either immediately
(immediate intervention group) or after a 12-week wait list period
(wait list control group) at a 1:1 ratio via an interactive voice andweb re-
sponse system. The randomization sequence was computer-generated
with random block sizes. Neither subjects nor investigators were blinded.
Study therapy
The total administered dose of IVIS (Venofer®) supplied by Luitpold
Pharmaceuticals was 1000 mg given at a dose of 200 mg per week. The
Table 2
Criteria for common anemia etiologies.
Conditions Criteria
Vitamin B12 deﬁciency Vitamin B12 b 200 pg/mL
Further diagnostic studies (e.g., methylmalonic acid) or a treatment trial may be considered
for a B12 level of 200–300 pg/dL. Oral or parental B12 treatment recommended.
Oral therapy should entail 1000 mcg or more daily.
A 3-month trial of B12 therapy with normalization of B12 level and ongoing anemia will
exclude B12 deﬁciency anemia and allow enrollment.
Folate deﬁciency Folate level b lower limit of normal
A 3-month trial of adequate folate correction and ongoing anemia will exclude
folate deﬁciency and allow enrollment.
Renal insufﬁciency Creatinine clearance by 4-variable MDRD of b30 mL/min
Thyroid dysfunction Thyrotropin b 0.1 mcU/mL or N 10 mcU/mL
3 Months of thyroid therapy with a normal free T4 and ongoing anemia will exclude
thyroid dysfunction and allow enrollment.
Myelodysplastic syndrome Myelodysplastic syndrome by bone marrow evaluation using the WHO criteria
A bone marrow examination should be performed if clinically indicated. Indications
include an MCV ≥ 100 fL, a platelet count b 120 K/uL, or a neutrophil count b 1200 K/uL
not attributable to another cause. A bone marrow evaluation should be considered if prior
chemotherapy, radiation therapy, an abnormal peripheral blood smear, or if over time the
MCV has been rising, platelets falling, or leukocyte count falling.
Anemia of chronic inﬂammation/disease Anemia in association with any inﬂammatory condition, including:
• Auto-immune diseases (systemic lupus erythematosis, rheumatoid arthritis, mixed connective
tissue disease, sarcoidoisis, bronchiolitis obliterans, vasculitis, polymyalgia rheumatica, temporal
arteritis, inﬂammatory bowel disease or related diseases) that are active or requiring systemic
treatment in the past 3 months. However, non-steroidal anti-inﬂammatory agents (e.g. ibuprofen),
acetaminophen, or aspirin as the sole systemic treatment will not be considered
active treatment and will allow enrollment.
• Chronic infection (HIV, viral hepatitis, tuberculosis, osteomyelitis) or acute infection
(pneumonia, sepsis, bacteremia, prostatitis, urosepsis, pyelonephritis, cholecystitis).
• Cancer. Any cancer (aside from non-melanoma skin cancer) in the past 2 years or on therapy for cancer.
In addition, prostate cancer will be excluded if subjects have metastatic disease, have had prostatectomy
within the prior 6 months, have ever received external beam radiation therapy or brachytherapy,
or have received androgen deprivation therapy in the prior 24 months. Subjects with a history of any
other form of cancer will likewise be excluded if they have received any radiation or chemotherapy
in the prior 24 months
• Treatment with immunosuppression may also be used as criteria as per the judgment of
the study investigator.
Plasma cell dyscrasia Multiple myeloma or plasma cell dyscrasia that may be causing anemia
Monoclonal gammopathy ≥ 1 g/dL.
A monoclonal paraprotein of b1 g/dL without bone lesions on skeletal survey, hypercalcemia,
b5% light chain restricted plasma cells, and no other evidence of progressive disease or multiple
myeloma will exclude a plasma cell dyscrasia and be allowable.
Thalassemia trait An MCV b 80 fL and red blood cell count within the normal reference range without iron deﬁciency
in the appropriate ethnic group. An elevated hemoglobin A2 (N3.5%) without iron deﬁciency on
hemoglobin electrophoresis or demonstrated two deletions for alpha thalassemia conﬁrms thalassemia trait.
A single alpha thalassemia deletion will not be excluded on this protocol. A documented decline of hemoglobin
of 1.5 g/dL over time without another cause except for baseline thalassemia will be acceptable to the protocol.
Alcohol Evidence of alcohol overuse
Overuse of alcohol will be determined by the clinician. Consider alcohol overuse if more than 3–4 drinks
per occasion for women and more than 4–5 drinks per occasion for men.
A trial of 3 months of using b3 drinks per week and ongoing anemia will exclude alcohol overuse.
Other Physical exam showing lymphadenopathy ≥ 2 cm or splenomegaly without another cause.
Any condition that can reasonably be assumed to be causing or a major contributor to the anemia
and has not been corrected for 3 months.
Any prior history of a hematologic malignancy.
Abbreviations: MDRD, Modiﬁcation of Diet in Renal Disease equation (186.3 × serum creatinine−1.154 × age−0.203 × [0.742 if female] × [1.212 if black]); WHO, World Health
Organization; MCV, mean cell volume.
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countered with administration of the ﬁrst dose, each subsequent dose
was administered over at least 15 min (or per local hospital pharmacy
policy) in a maximum of 100 mL 0.9% sodium chloride. Monitoring in-
cluded assessment of vital signs at baseline and every 15 min during
the infusion and 15 min postinfusion.Study outcomes
The primary outcome was changed in 6MWT distances from base-
line to 12 weeks. The primary outcome was chosen to assess whether
iron repletion would improve functional impairment, which is of highimportance in geriatric populations. Secondary outcomes included the
change from baseline to 12 weeks for hemoglobin measurement, and
quantiﬁcation of the impact of anemia treatment on functional and
self-report outcome measures as assessed by the Geriatric Evaluation
Panel (GEP), consisting of the following:
- Cognitive function based on the Trail Making Test and four
CogState® cognitive subtests;
- Quality of life as measured by the 36-Item Short FormHealth Survey
(SF-36) physical component summary subscale and the Functional
Assessment of Cancer Therapy–Anemia (FACT-An);
- Four components of the frailty index: grip strength, 4-mwalk speed,
self-reported exhaustion, and self-reported activity level.
224 E. Price et al. / Blood Cells, Molecules and Diseases 53 (2014) 221–230For reporting purposes, the secondary outcomes based on the GEP
are summarized as follows:
1. Physical function: 4-m walk speed obtained as a component of the
frailty index (see below);
2. Cognitive function: primary cognitive outcome of Trail Making Test
Part B in seconds per completed circle, with shorter time representing
better executive function and cognitive ﬂexibility, and secondary cog-
nitive outcomes with three cognitive composite Z-scores, with higher
score indicating better cognitive function (see Appendix B for deﬁni-
tions)—composite speed of processing Z-score, composite complex at-
tention/executive processing Z-score, and composite learning and
memory Z-score;
3. Quality of life: SF-36 physical component summary score and FACT-
An Total Score;Screened 
Randomize
Immediate Intervention Group  
(N = 9) 
Completed Treatment (N = 9) 
Discontinued Treatment (N = 0) 
Completed 12 Week Visit (N = 9) 
Did Not Complete 12 Week Visit (N= 0)
Primary Analysis (N = 9) 
Week 12 6-MWT Performed (N = 9) 
Week 12 6-MWT Not Performed (N = 0) 
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Fig. 1. Flow of stu4. Four binary components of frailty index as deﬁned by the Women's
Health and Aging Studies criteria [18] (see Appendix C): exhaustion
(self-reported), low energy (based on self-reported activity level),
weakness (based on grip strength), and slowness (based on 4-m
walking speed). The overall frailty score based on the ﬁve compo-
nents (includingweight loss) of the frailty indexwas also used to de-
scribe the population at baseline.
TheGEPwas administered to each subject during the screening period
and at weeks 12 and 24. The 6MWTwas additionally measured at weeks
6 and 18. Safety outcomes included all clinical and reportable events.
Statistical considerations
We calculated that a sample size of 84 subjects, with 42 subjects per
group, would provide 84% power to detect a clinical signiﬁcant(N = 43) 
Screen Failures (N = 24) 
 Lost to Follow-up (N = 1) 
   Consent Withdrawn (N = 6) 
   Subject Ineligible for Study (N = 17) 
Hemoglobin Not within Range (n=9) 
 Serum Ferritin Level Not within Range (n=4) 
 Not Able to Walk without Assistance (n=1) 
 Montreal Cognitive Assessment Score <22 (n=1) 
 Hemoglobin Not within Range, History of CVA/ 
      TIA in the Past 3 Months and Uncontrolled 
      Hypertension (n=1) 
 Hemoglobin Not within Range and Positive  
     Screening Fecal Occult Blood Test (n=1) 
d (N = 19) 
Wait List Group  
(N = 10) 
Completed 12 Week Visit (N = 10) 
Did Not Complete 12 Week Visit (N= 0)
Primary Analysis (N = 10) 
Week 12 6-MWT Performed (N = 9) 
Week 12 6-MWT Not Performed (N = 1) 
dy subjects.
Table 3
Characteristics of unexplained anemia subjects at baseline.
Demographic and clinical
characteristics
Immediate
intervention
group
(N = 9)
Wait list
control
group
(N = 10)
Age at randomization (years) 78.6 ± 6.1 78.5 ± 7.4
Female sex, n (%) 6 (66.7) 5 (50.0)
Race, n (%)
White 3 (33.3) 6 (60.0)
Black or African American 6 (66.7) 3 (30.0)
Asian 0 1 (10.0)
Medical history, n (%)
Hypertension 7 (77.8) 6 (60.0)
Diabetes 2 (22.2) 5 (50.0)
Medications, n (%)
Acetylsalicylic acid 4 (44.4) 8 (80.0)
Oral iron at screening 1 (11.1) 1 (10.0)
Vitamin B12 1 (11.1) 1 (10.0)
MoCA score 25.9 ± 2.1 24.9 ± 2.3
Symptoms of anemia at enrollment, n (%)
Dizziness 1 (11.1) 0
Pallor 1 (11.1) 3 (30)
Shortness of breath 3 (33.3) 1 (10)
Fatigue 7 (77.8) 5 (50)
No symptoms reported 1 (11.1) 0
Baseline laboratory values
Hemoglobin (g/dL) 11.19 ± 0.64 11.30 ± 0.80
Hematocrit (%) 33.77 ± 1.86 35.62 ± 2.52
Mean corpuscular volume (fL) 89.94 ± 6.84 92.48 ± 8.09
Red cell distribution width (%) N = 9
14.76 ± 1.31
N = 9
14.78 ± 0.99
Reticulocyte count, absolute (109/L) N = 7
48.4 ± 13.5
N = 8
45.2 ± 6.7
Serum iron (mcg/dL) 55.3 ± 10.2 84.5 ± 25.4
Serum ferritin (ng/mL) 79.1 ± 54.1 53.0 ± 26.1
Total iron binding capacity (mcg/dL) 313.3 ± 49.1 321.3 ± 71.7
Transferrin saturation (%) 17.9 ± 4.0 27.4 ± 9.7
Serum erythropoietin (mIU/mL)
Creatinine (mg/dL) 1.16 ± 0.19 1.27 ± 0.13
eGFR (ml/min/1.73 m2)a N = 4
51.5 ± 7.0
N = 8
52.0 ± 5.4
eGFR category, n (%)
30–59 4 (44.4) 8 (80)
≥60 5 (55.6) 2 (20)
High-sensitivity C-reactive protein (mg/L) N = 9
4.712 ± 5.258
N = 8
1.961 ± 2.210
Geriatric evaluation panel
Physical function
Baseline 6MWT results (m) 351.40 ± 67.01 344.80 ± 90.30
Baseline 4-m walk speed —
usual walking speed (m/s)
N = 6
0.736 ± 0.0220
N = 8
1.020 ± 0.430
Baseline 4-m walk speed —maximum
walking speed (m/s)
N = 7
1.054 ± 0.224
N = 8
1.325 ± 0.393
Cognitive function
Wechsler Test of adult reading
standard score
N = 7
107.6 ± 21.4
N = 10
100.0 ± 23.6
Trail making test part B, seconds per
completed circle
N = 9
6.37 ± 3.18
N = 6
14.43 ± 14.82
Composite speed of processing Z-score N = 8
0.16 ± 0.97
N = 10
−0.13 ± 1.06
Composite complex attention/
executive processing Z-score
N = 9
0.15 ± 0.80
N = 9
−0.15 ± 1.20
Composite learning and memory
Z-score
N = 7
0.69 ± 0.67
N = 10
−0.48 ± 0.92
Frailty, n/N (%)
Weight loss 0/7 (0) 2/9 (22.2)
Exhaustion 1/9 (11.1) 1/10 (10.0)
Low energy 0/7 (0) 0/8 (0)
Weakness based on grip strength 1/6 (16.7) 4/8 (50.0)
Slowness based on 4-m walk speed 2/5 (40) 1/8 (12.5)
Overall frailty score, n/N (%)
Robust 1/4 (25) 3/6 (50)
Pre-frail 3/4 (75) 2/6 (33.3)
Frail 0/4 (0) 1/6 (16.7)
(continued on next page)
Table 3 (continued)
Demographic and clinical
characteristics
Immediate
intervention
group
(N = 9)
Wait list
control
group
(N = 10)
Quality of life
Baseline SF-36 physical component
summary score
43.65 ± 6.70 48.80 ± 7.87
Baseline FACT-An total score N = 9
147.9 ± 28.7
N = 8
156.4 ± 23.9
Therewere no signiﬁcant differences between the groups except serum iron (p = 0.006),
transferrin saturation (p = 0.015), and the composite learning and memory Z-score
(p = 0.012). Plus–minus values are mean ± SD (N reported if at least one subject in ei-
ther treatment group was missing a response for the baseline characteristic).
Abbreviations: MoCA, Montreal Cognitive Assessment; eGFR, estimated glomerular ﬁltra-
tion rate; 6MWT, 6-minutewalk test; SF-36, 36-Item Short FormHealth Survey; FACT-AN,
Functional Assessment of Cancer Therapy–Anemia.
a Results b 60 only.
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tween the immediate intervention group and the wait list control
group, with a type I error rate of 0.05. This calculation was based on a
two-sample t-test by assuming a standard deviation of 115 m for the
baseline 6MWT distance in both groups and correlations of 0.7 and 0.9
between distances at baseline and 12 weeks for the immediate inter-
vention and wait list control groups, respectively. This sample size also
took into account a 10% missing data rate.
Baseline characteristics were summarized using descriptive statis-
tics, with categorical data presented as percentages and continuous
data presented as the mean plus/minus standard deviation. Differences
between treatment groups were assessed using a chi-square test or
Fisher's exact test (for small frequencies) for categorical data, and a t-
test or Wilcoxon test (for non-normal data) for continuous data. The
primary endpoint of change in 6MWT distances from baseline to
12 weeks between the two groups was tested using the two-sample t-
test. All intent-to-treat patients were included in the primary analysis
with an assumption that any missing data were missing completely at
random. The impact of missing data in the primary analysis was exam-
ined by sensitivity analyses based on best and worst case scenarios for
imputing themissing change. Per-protocol analysis was also performed
on the primary outcome where the per-protocol population included
only patients enrolled with eligible criteria who received the assigned
treatment. All secondary outcomeswere analyzed as exploratory analy-
ses with a chi-square test or Fisher's exact test for categorical data and a
t-test orWilcoxon test for continuous data. The level of statistical signif-
icance for all analyses was 0.05, and all analyses were two-sided. All
analyseswere performedwith SAS software, version 9.2 (SAS, Cary, NC).
Results
Disposition and baseline characteristics of the study subjects
The study enrollment was from May 2011 to November 2012. The
study was terminated early at DSMB recommendation after only 19
subjectswere enrolled; poor enrollment persisted despite numerous re-
cruitment initiatives. As shown in Fig. 1, 43 subjects were identiﬁed as
potentially eligible and underwent formal screening. Of these 43 sub-
jects, 17 were ineligible, one was lost to follow up, and six withdrew
consent. The remaining 19 subjects were randomized, nine to the im-
mediate intervention group and 10 to the wait list control group. All
subjects in the immediate intervention group completed the study. An
additional patient in the wait list control group missed the 12-week
6MWT. The clinical characteristics of the 19 enrolled subjects are pre-
sented in Table 3. The mean age was 78.5 years, and 58% of enrolled
226 E. Price et al. / Blood Cells, Molecules and Diseases 53 (2014) 221–230subjects were female. The two randomized groups were similar with
respect to key baseline clinical and laboratory characteristics, includ-
ing serum ferritin, except for a few variables such as lower serum
iron (55.3 vs. 84.5 mcg/dL, p = 0.006), lower transferrin saturation
(17.9% vs. 27.4%, p = 0.015), and better composite learning and
memory Z-score (0.69 vs.−0.48, p= 0.012) in the immediate inter-
vention group.
Safety
Overall, the study intervention was well tolerated. A total of seven
subjects in the immediate intervention arm and four subjects in the
wait list control group had at least one treatment emergent adverse
event reported. Two subjects in the immediate intervention group ex-
perienced what were deemed possibly treatment-related events
(one patient reported back pain, and one reported cough), while one
patient in the wait list control group reported nausea and “feeling hot”
as probably treatment-related events. All of the possibly or probably
treatment-related events were reported as mild. Two subjects expe-
rienced serious adverse events. One 87-year-old subject had acute
cholecystitis 95 days after the ﬁrst dose of study drug, as well as a
urinary tract infection 171 days after the ﬁrst dose of study drug. An-
other 80-year-old subject suffered a pelvic fracture and syncope,
both 62 days after the ﬁrst dose of study drug. None of the serious ad-
verse events was considered to be treatment-related, and all
resolved.
Primary outcome
At baseline, the immediate intervention group walked a mean of
351.4 ± 67.01 m and the wait list control group walked a mean of
344.80± 90.30 m in 6min (p= 0.860), whichwere below the expect-
ed values for 75- to 79-year-oldwomen andmen (Appendix A). Primary
analysis showed that the mean change in distance walked at 12 weeks
was an increase of 8.05± 55.48m in the immediate intervention group
and a decrease of 11.45 ± 49.46 m in the wait list control group (p =
0.443) (Table 4, Fig. 2). Sensitivity analyses with imputation of data
for the one subject in the wait list control group who had missing data
on the 6MWT at 12 weeks were based on the best and worst scenarios,
and yielded similar results (data not shown). The per-protocol analysis
excluded one female subject who was incorrectly randomized but
ineligible by hemoglobin criteria (with initial screening hemoglobin of
10.8 g/dL and a subsequent hemoglobin value drawn 12 days later of
11.5 g/dL, thus rendering her ineligible) and showed similar results
(data not shown).
Secondary outcomes
Therewas a small but statistically signiﬁcant increase in hemoglobin
of 0.39 ± 0.46 g/dL at 12 weeks in the immediate intervention group
compared to a decline in hemoglobin of 0.39 ± 0.85 g/dL in the wait
list control group (p = 0.026, Table 4). One patient in each group had
an increase in hemoglobin of at least 1 g/dL 12 weeks after receiving
theﬁrst dose of IVIS (received immediately after screening in the imme-
diate intervention group and after 12 weeks in the wait list control
group). Over time,mean hemoglobin levels rose in the immediate inter-
vention group but decreased in thewait list control group (Fig. 3).Mean
hemoglobin levels rose slightly in each study group 12 weeks after ini-
tiation of treatment with IVIS (from 11.19 g/dL to 11.58 g/dL in the im-
mediate intervention group, and from 10.91 g/dL to 12.01 g/dL in the
wait list control group). There were no signiﬁcant differences in the
two groups in change at 12 weeks for other secondary outcomes of
physical, cognitive function, quality of life, and frailty (Table 4). There
were no statistically signiﬁcant correlations between the week 12
change in hemoglobin from baseline and any of the iron indices atbaseline in either the immediate intervention group or thewait list con-
trol group (data not shown).
Discussion
This is theﬁrst exploratory intervention study aimed solely at treating
older adults with UAE utilizing intravenous iron. We treated subjects
with UAE and serum ferritin levels between 20 and 200 ng/mL (inclu-
sive) with ﬁve weekly 200-mg doses of IVIS. Unfortunately, because of
early termination of the study due to poor recruitment, the study is sub-
stantially underpowered to detect differences in the primary outcome.
Thus, although the direction of changes in 6MWT results were as hy-
pothesized—that is, the 6MWT improved in the immediate intervention
group compared to the wait list control group—the differences between
the groups were not signiﬁcant. These results are compatible with a trial
in older adults with heart failure and similar ferritin levels treated with
intravenous ferric carboxymaltose [19]. In that randomized, placebo-
controlled study, the 304 subjects assigned to the ferric carboxymaltose
arm had a mean increase in 6MWT results from 274 m to 312 m at 12-
week follow-up, signiﬁcantly higher than seen in the placebo group.
The differing statistical signiﬁcance of the results between the two
studies may be explained by the very low numbers in our study ham-
pering our ability to detect a signiﬁcant difference in 6MWT results.
Alternative possibilities include the differing study populations (un-
explained anemia vs. congestive heart failure), dose and formulation
of intravenous iron given, and baseline 6MWT results, which were
higher in our study.
The study interventionwaswell tolerated, and therewere no serious
adverse events considered to be related to the study drug. With regard
to secondary outcomes, a modest increase in hemoglobin was seen in
the immediate intervention group compared to the wait list control
group at 12 weeks. In addition, one patient in each group had an in-
crease of at least 1 g/dL in hemoglobin at 12 weeks following initiation
of IVIS. This suggests the possibility that a subgroup of subjects with
UAEmay respond to parenteral iron therapy. Interestingly, the increase
in hemoglobin was not correlated with iron indices, although again,
small numbers preclude making more deﬁnitive observations about
these ﬁndings.
One of the lessons learned was the great difﬁculty in recruiting sub-
jects to this type of study. All of the participating institutionswere well-
established clinical trial sites with histories of robust accrual to clinical
trials. Subjectswere vigorously recruited throughmultiplemechanisms,
including specialty clinic and primary care referrals, the placement of
study ﬂyers at hospital and clinic sites, newspaper advertisements, the
mailing of thousands of ﬂyers to targeted population areas, electronic
medical record searching, chart reviews, and investigator-led anemia
lectures at local community and senior centers. Approximately 1000
subjects were voluntarily reported by the sites to have been
prescreened for the study. Nonetheless, despite intense recruitment ef-
forts, including targeted mailing, which in some studies of the elderly
has been shown to be the most effective recruitment maneuver [20,
21], enrollment remained poor and the study was terminated early.
Poor recruitment was likely driven by multiple factors, including the
general clinician tendency to ignore typically mild anemia in older
adults in the face of more prominent medical issues, the complex re-
quirements for this study, including extensive functional testing, and
the logistical difﬁculties for older adults in participating in intervention-
al studies with involved follow-up. One of the most important barriers
to recruitment was the overly restrictive eligibility criteria, which led
to the exclusion of many subjects. In addition, the negative results
from studies using erythropoietic agents may have blunted enthusiasm
for anemia trials in general [22–24].
Nonetheless, the issues remain of clinical importance. Although it is
unknownwhether anemia itself causes the extensivemorbidity ormor-
tality seen in older anemic adults, it is plausible to suggest that anemia,
potentially leading to local tissue hypoxia, could aggravate functional
Table 4
Change from baseline for outcome measures at week 12.
Outcome measures Immediate intervention
group
Wait list control
group
Mean difference between groups (95% conﬁdence
interval)
P
valuea
Primary outcome
6MWT (m) N = 9
8.05 ± 55.48
N = 9
−11.45 ± 49.46
19.50
(−33.02–72.02)
0.443
Secondary outcomes
Hemoglobin (g/dL) N = 9
0.39 ± 0.46
N = 10
−0.39 ± 0.85
0.78
(0.11–1.45)
0.026
Geriatric evaluation panel
Physical function
4-m walk speed — usual walking speed (m/s) N = 5
0.420 ± 0.590
N = 6
−0.026 ± 0.081
0.45
(−0.28–1.17)
0.167
4-m walk speed —maximum walking speed (m/s) N = 6
0.413 ± 1.107
N = 6
0.093 ± 0.303
0.32
(−0.84–1.48)
0.744
Cognitive function
Trail making test part B seconds per completed circle N = 9
−0.77 ± 3.54
N = 5
−4.96 ± 8.14
4.18
(−5.74–14.11)
0.325
Composite speed of processing Z-score N = 8
0.62 ± 1.00
N = 9
1.08 ± 0.88
−0.46
(−1.43–0.51)
0.330
Composite complex attention/executive processing
Z-score
N = 9
0.36 ± 1.28
N = 8
0.69 ± 1.19
−0.33
(−1.61–0.96)
0.595
Composite learning and memory Z-score N = 7
0.41 ± 1.50
N = 7
1.39 ± 2.36
−0.98
(−3.28–1.33)
0.374
Quality of life
SF-36 physical component summary score N = 8
−1.89 ± 2.44
N = 9
−3.17 ± 10.95
1.28
(−7.22–9.78)
0.741
FACT-An total score N = 8
10.6 ± 10.0
N = 6
0.0 ± 34.7
10.6
(−25.7–47.0)
0.495
Frailty change from frail at baseline to not frail at week 12
Exhaustion 1/9 (11.1) 1/8 (12.5) NA N0.999
Low energy 0/7 (0) 0/5 (0) NA NA
Weakness 0/6 (0) 0/7 (0) NA NA
Slowness 0/4 (0) 0/6 (0) NA NA
Plus–minus values are mean ± SD.
Abbreviations: 6MWT, 6-minute walk test; SF-36, 36-Item Short Form Health Survey; FACT-An, Functional Assessment of Cancer Therapy–Anemia.
a For the continuous variables, p-values are based on t-tests except for data that were not normally distributed, where Wilcoxon test p-values are reported; for categorical
variables, p-values are based on Fisher's exact tests.
Age
(years)
Women
(meters)
Men
(meters)
65–69 521 576
70–74 503 558
75–79 466 512
80–84 421 485
85–89 375 439
N90 311 366
227E. Price et al. / Blood Cells, Molecules and Diseases 53 (2014) 221–230decline and, furthermore, that treatment of anemia has the potential to
ameliorate some, if not all, of these signiﬁcant negative effects.
This trial involved performing a comprehensive battery of physi-
cal, cognitive, quality of life, and frailty tests. Although the ﬁndings
were modest, this study shows that it is feasible to perform compre-
hensive evaluations in this population. Such investigation could
form the basis for future studies in older anemic adults to better as-
certain the exact beneﬁts across relevant domains of physical func-
tion, cognition, quality of life, and frailty. Future trials focusing on
treatment of UAE should utilize streamlined, patient-friendly design,
minimal entry criteria, and intensive recruitment efforts tailored to-
ward older adults. It will also be critical for future studies of UAE to
signiﬁcantly expand the patient recruitment base by increasing the
numbers of participating institutions.
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Appendix A. Upper 6MWT distances for exclusion as speciﬁed by age
and sex
Fig. 2. 6-minute walk test (6MWT) distance by study week. Solid line joins the average 6MWT distance (meters) for each treatment group. The bottom and top of the boxes are the 25th
and 75th percentiles, the line in the box is the median, and the ends of the whiskers are the 5th and 95th percentiles.
228 E. Price et al. / Blood Cells, Molecules and Diseases 53 (2014) 221–230Appendix B. Cognitive function outcomes
Eight cognitivemeasures based on the Trail Making Test (TMT) Parts
A and B and the CogState assessments are deﬁned as follows:
• TMT
○ Seconds per completed circle in TMT Part A (seconds per complet-
ed circle calculated from the time to complete the task [25 circles]
or the number of circles completed in 180 s)
○ Seconds per completed circle in TMT Part B (seconds per complet-
ed circle calculated from the time to complete the task [25 circles]
or the number of circles completed in 300 s).
• CogState assessments (unit of measurement)
○ Simple reaction time from the CogState Detection task (log10 ms)
○ Choice reaction time from theCogState Identiﬁcation task (log10ms)
○ Time score from the CogState One-Back task (log10 ms)
○ Accuracy score from the CogState One-Back task (arcsine
transformation of the square root of the proportion of correct re-
sponses)
○ Immediate recall score from the CogState International Shopping List
(ISL) (number of correct responses)
○ Delayed recall score from the CogState ISL (number of correct
responses).
In this paper, seconds per completed circle in TMT Part B is the
primary cognitive outcome, with shorter time indicating better
cognitive function.In addition, three composite scores will be derived using the Z-scores
speciﬁed below for each composite:
• Speed of processing: (1) TMT Part A seconds per completed circle,
(2) simple reaction time from the CogState Detection Task, and
(3) choice reaction time from the CogState Identiﬁcation Task
• Complex attention/executive processing: (1) TMT Part B seconds per
completed circle, (2) time score from the CogState One Back Task,
and (3) accuracy score from the CogState One Back Task
• Learning and memory: (1) CogState ISL immediate recall score (total
score from three learning trials), (2) CogState ISL immediate recall
score from the ﬁrst learning trial, and (3) CogState ISL delayed recall
scores.
The composite score for a subject at each time point will be de-
ﬁned as the mean of the Z-scores speciﬁed above for each composite
at the time point. If one of the scores speciﬁed is missing, the mean
was based on the available scores. The Z-score for each item at
each time was derived by subtracting the overall baseline mean
and then divided by the overall baseline standard deviation of this
item. In order for all positive Z-scores to indicate a better cognitive
function compared to the baseline average, a negative sign was
added to the Z-scores for the TMT seconds per completed circle
and the CogState time score from the One-Back Task, simple reaction
time from the Detection Task, and choice reaction time from the
Identiﬁcation Task.
Fig. 3.Hemoglobin (g/dL) by study week. Solid line joins the average hemoglobin for each treatment group. The bottom and top of the boxes are the 25th and 75th percentiles, the line in
the box is the median, and the ends of the whiskers are the 5th and 95th percentiles.
Cutoff for 4-meter usual walking speed criterion for frailty
Men
Height ≤ 173 cm ≤0.65 m/s
Height N 173 cm ≤0.76 m/s
Women
Height ≤ 159 cm ≤0.65 m/s
Height N 159 cm ≤0.76 m/s
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components of frailty index
Based onWomen's Health and Aging Studies (WHAS) criteria* [18]:
• Weight loss: If any of the following three criteria are met, the subject
will be classiﬁed as frail for weight loss:
1. Body mass index at baseline is b18.5 kg/m2.
2. “In the last year, have you lost more than 10 lb unintentionally (i.e.,
not due to dieting or exercise)?” is answered “yes.”
3. Weight loss deﬁned as weight in the previous year− baseline mea-
sured weight) / (weight in previous year) ≥ 0.05 and the loss was
unintentional.
• Subjective fatigue/exhaustion: If any of the following three criteria are
met, the patient will be classiﬁed as frail for fatigue/exhaustion:
1. “In the pastmonth, on average, have you been feeling unusually tired
during the day?” is answered “yes” and indicated as “all of the time”
or “most of the time”.
2. “In the pastmonth, on average, have you felt unusually week?” is an-
swered “yes” and indicated as “all of the time” or “most of the time”.
3. Energy level on a scale of 0 (no energy) to 10 (most energy) reported
as ≤3.
• Physical activity: Using six physical activities (walking for exercise,
moderately strenuous household chores, moderately strenuous out-
door chores, dancing, bowling, regular exercise) condensed from theoriginal 18 activities in the short version of the Minnesota Leisure
Time Activity questionnaire, kilocalories (Kcals) per week expended
are calculated utilizing a standardized algorithm. This variable is strat-
iﬁed by gender:
○ Men with Kcals of physical activity per week b 128 are frail.
○ Women with Kcals per week b 90 are frail.
• 4-meterwalking speed (converted from cutpoints based on 15-foot walk-
ing time), stratiﬁed by gender and height (gender-speciﬁc cutoff = a
medium height):If no walking speed is reported, subjects will be classiﬁed as frail for
walking speed if they tried but were unable to walk, even with sup-
port, or if the examiner/subject felt it was unsafe to walk.
230 E. Price et al. / Blood Cells, Molecules and Diseases 53 (2014) 221–230• Grip strength, stratiﬁed by gender and body mass index (BMI)
quartiles:Cutoff for grip strength criterion for frailty [25]
Men
BMI ≤ 24 ≤29
BMI 24.1–26 ≤30
BMI 26.1–28 ≤30
BMI N 28 ≤32
Women
BMI ≤ 23 ≤17
BMI 23.1–26 ≤17.3
BMI 26.1–29 ≤18
BMI N 29 ≤21The frailty criteria above will be used to deﬁne frailty for each of the
ﬁve components (weight loss at baseline only). This will result in
ﬁve binary outcomes for the ﬁve components of frailty. An overall
frailty score (range from 0 to 5) will be calculated at baseline by sum-
ming the ﬁve binary outcomes. The combined binary frailty outcome
(Yes/No) will be deﬁned with cutpoint of 3 where subjects with an
overall score of 3 or higher are considered as frail. Score of 1–2 is
considered as pre-frail, and 0 is considered as robust. Only four com-
ponents (grip strength, walking speed, fatigue/exhaustion, and phys-
ical activity) will be measured postbaseline as outcomes.
*Frailty index was derived using the WHAS criteria except for weight
loss. In this study, weight is only collected at baseline. Therefore, frail-
ty forweight loss is based on BMI b 18.5 kg/m2 at baseline fromWHAS
and from the Cardiovascular Health Study (CHS), unintentional
weight loss of N10 lb in the last year assessed at baseline as well as
≥5% unintentional weight loss at baseline compared to the previous
year (instead of at follow-up compared CHS criteria).
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